| Literature DB >> 25180086 |
H C Anyabolu1, E A Adejuyigbe1, O O Adeodu1.
Abstract
Background. Though micronutrients are vital in the pathogenesis of human immunodeficiency virus infection, most studies have been conducted in adults. Knowledge of the status of key micronutrients in HIV infected African children will indicate if supplementation may be beneficial to these children living in this resource-poor region. Objectives. We sought to determine the micronutrient status and associated factors of HAART-naïve HIV infected children and compare them with those of the HIV negative controls. Methods. We enrolled 70 apparently stable HAART naïve HIV infected children. Seventy age and sex matched HIV negative children were equally enrolled as the controls. Their social class, anthropometry, clinical stage, CD4 counts, serum zinc, selenium, and vitamin C were determined. Results. The prevalence of zinc, selenium, and vitamin C deficiency in HIV infected subjects was 77.1%, 71.4%, and 70.0%, respectively, as compared to 44.3%, 18.6%, and 15.7% in HIV negative controls. Among the HIV infected subjects, 58.6% were deficient in the three micronutrients. Micronutrient status was related to the weight, clinical, and immunological stages but not BMI or social class. Conclusion. Deficiency of these key micronutrients is widely prevalent in HAART naïve HIV infected children irrespective of social class. This suggests that supplementation trial studies may be indicated in this population.Entities:
Year: 2014 PMID: 25180086 PMCID: PMC4144154 DOI: 10.1155/2014/351043
Source DB: PubMed Journal: AIDS Res Treat ISSN: 2090-1240
Demographic, clinical, and micronutrient data of HIV infected subjects and the HIV negative controls.
| Variables | Infected | Control |
|---|---|---|
| Age range (mths) | 24–180 | 24–180 |
| Age group | ||
| 18–59 mths ( | 43 (61.4) | 43 (61.4) |
| 60–119 mths ( | 21 (30.0) | 22 (31.4) |
| 120–227 mths ( | 6 (8.6) | 5 (7.1) |
| Mean age ± SD (mths) | 58.4 ± 37.8 | 58.01 ± 38.1 |
| Gender (M versus F) | 40 versus 30 | 39 versus 31 |
|
| ||
|
∗Social class ( | ||
| I | — | 9 (112.9) |
| II | 14 (20.0) | 19 (27.1) |
| III | 16 (22.9) | 15 (21.4) |
| #IV | 27 (38.9) | 13 (18.6) |
| V | 13 (18.6) | 14 (20.0) |
|
| ||
| Anthropometry Z scores | ||
| #Median WAZ (25, 75) male | −0.18 (−0.62, 0.59) | −0.35 (−0.54, 0.38) |
| Median WAZ (25, 75) female | −0.53 (−0.81, 0.36) | −0.51 (−0.66, −0.15) |
| Median HAZ (25, 75) male | −0.13 (−0.67, 0.70) | −0.22 (0.68, 0.79) |
| Median HAZ (25, 75) female | −0.61 (−0.88, 0.46) | −0.53 (−0.83, 0.18) |
| #Median WHZ (25, 75) male | −1.34 (−2.29, −0.21) | −0.34 (−0.89, 0.09) |
| #Median WHZ (25, 75) female | −1.13 (−1.87, −0.44) | −0.32 (−1.11, 0.00) |
|
| ||
| #Mean ± SD serum albumin (g/L) | 3.2 ± 0.7 | 4.0 ± 0.5 |
| #Mean ± SD CD4 count (cells/mL) | 611.4 ± 444.5 | 1388.2 ± 556.5 |
| #Mean ± SD CD4 % (%) | 18.8 ± 13.2 | 35.4 ± 4.4 |
|
| ||
| Clinical stage ( | ||
| 1 | 8 (11.4) | — |
| 2 | 15 (21.4) | — |
| 3 | 31 (44.3) | — |
| 4 | 16 (22.9) | — |
|
| ||
| Immunological stage [n (%)] | ||
| Not significant immunosuppression | 4 (5.7) | — |
| Mild significant immunosuppression | 15 (21.4) | — |
| Advanced significant immunosuppression | 18 (25.7) | — |
| Severe significant immunosuppression | 33 (47.1) | — |
|
| ||
| Serum micronutrient (mean ± SD) | ||
|
#Zinc ( | 66.99 ± 16.7 | 82.78 ± 25.8 |
|
#Vitamin C ( | 0.41 ± 0.29 | 0.78 ± 0.28 |
|
#Selenium ( | 7.26 ± 0.2 | 9.81 ± 1.6 |
|
| ||
| Low albumin [ | 40 (57.1) | 7 (14.9) |
|
| ||
| Micronutrient deficiency [n (%)] | ||
| #Zinc deficient | 54 (77.1) | 31 (44.3) |
| #Selenium deficient | 50 (71.4) | 13 (18.6) |
| #Vitamin C deficient | 49 (70.0) | 11 (15.7) |
∗By Oyedeji [19]. # P < 0.05.
Figure 1The relationship between Serum zinc levels and clinical stage of HIV infected subjects.
Figure 2The relationship between serum selenium levels and clinical stage of HIV infected subjects.
Figure 3The relationship between serum vitamin C levels and clinical stage of HIV infected subjects.
Relationship between the mean serum micronutrient levels and CD4 categories of the HIV infected subjects.
|
| Selenium (mean ± SD) |
| Zinc (mean ± SD) |
| Vitamin C (mean ± SD) | ||
|---|---|---|---|---|---|---|---|
| CD4 < 350 | 25 | 6.11 ± 1.09 | 0.0001 | 58.70 ± 16.53 | 0.002 | 0.34 ± 0.15 | 0.005 |
| CD4 ≥ 350 | 45 | 7.97 ± 1.67 | 71.99 ± 15.07 | 0.46 ± 0.18 | |||
|
| |||||||
| CD4 < 25% | 61 | 6.93 ± 1.53 | 0.0001 | 64.52 ± 16.0 | 0.001 | 0.39 ± 0.17 | 0.014 |
|
| 9 | 9.52 ± 1.34 | 83.69 ± 11.53 | 0.57 ± 0.18 | |||
N is the number of infected HIV subjects in that CD4 category.
P is significant at <0.05.
Correlation of albumin with serum micronutrients level in HIV infected subjects.
| Albumin versus zinc | Albumin versus selenium | Albumin versus vitamin C | |
|---|---|---|---|
|
| 0.386 | 0.466 | 0.377 |
|
| 0.001 | 0.001 | 0.001 |
|
| 70 | 70 | 70 |
N: number of HIV infected subjects.
r: correlation coefficient.
P is significant <0.05.
Predictors of serum selenium, zinc, and vitamin C in HIV infected subjects.
| Predictor# | Selenium | Zinc | Vitamin C | |||
|---|---|---|---|---|---|---|
| Coefficient (CI) |
| Coefficient (CI) |
| Coefficient (CI) |
| |
| Social class 2 | 0.91 (−0.12, 1.93) | 0.08 | 0.30 (−9.00, 9.61) | 0.95 | 0.07 (−0.06, 0.21) | 0.28 |
| Social class 4 | 0.36 (−0.61, 1.33) | 0.46 | 6.71 (−3.19, 16.61) | 0.18 | 0.02 (−0.11, 0.15) | 0.72 |
| Social class 3 | 0.73 (−0.08, 1.55) | 0.08 | 4.71 (−4.15, 13.33) | 0.29 | 0.06 (−0.05, 0.17) | 0.25 |
| Social class 5 | 0 (−1.00, 1.00) | 1.00 | −0.22 (−11.06, 10.63) | 0.97 | 0 (−0.14, 0.14) | 1.0 |
| BMI | −0.82 (−0.29, 0.13) | 0.43 | 0.09 (−2.14, 2.32) | 0.08 | −0.00 (−0.03, 0.02) | 0.87 |
| Clinical stage 2 | −1.52 (−2.66, 0.37) | 0.01∗ | −11.02 (−23.33, 1.29) | 0.94 | −0.01 (−0.16, 0.14) | 0.87 |
| Clinical stage 3 | −3.59 (−4.73, −2.45) | <0.001∗ | −29.12 (−41.50, −16.74) | 0.001∗ | −0.18 (−0.33, −0.03) | 0.02∗ |
| Clinical stage 4 | −3.70 (−5.02, −239) | <0.001∗ | −30.64 (−45.85, −15.45) | 0.001∗ | −0.28 (−0.45, −0.10) | 0.002∗ |
| Mild immunosuppression | −0.40 (01.64, 0.84) | 0.52 | −1.52 (−16.31, 13.27) | 0.01∗ | −0.20 (−0.37, −0.02) | 0.03∗ |
| Advanced immunosuppression | −3.10 (−4.45, −1.95) | <0.001∗ | −18.63 (−32.72, −4.55) | 0.001∗ | −0.35 (−0.51, −0.18) | 0.001∗ |
| Severe immunosuppression | −3.20 (−4.28, −1.91) | <0.001∗ | −25.05 (−39.90, −10.21) | 0.001∗ | −0.39 (−0.56, −0.22) | 0.001∗ |
#Social class 1, Clinical stage 1, and insignificant immunosuppression results were the references.
*P values were significant (P < 0.05).
The test of linearity and influential points proved the fit of the regression model.